CLASS ACTION UPDATE for BLUE, OTRK and ATNX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / April 8, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
BLUE Shareholders Click Here: https://www.zlk.com/pslra-1/bluebird-bio-inc-loss-form?prid=14490&wire=1
OTRK Shareholders Click Here: https://www.zlk.com/pslra-1/ontrak-inc-loss-submission-form?prid=14490&wire=1
ATNX Shareholders Click Here: https://www.zlk.com/pslra-1/athenex-inc-loss-submission-form?prid=14490&wire=1
* ADDITIONAL INFORMATION BELOW *
bluebird bio, Inc. (NASDAQ:BLUE)
BLUE Lawsuit on behalf of: investors who purchased May 11, 2020 - November 4, 2020
Lead Plaintiff Deadline : April 13, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/bluebird-bio-inc-loss-form?prid=14490&wire=1
According to the filed complaint, during the class period, bluebird bio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) data supporting bluebird's BLA submission for LentiGlobin for SCD was insufficient to demonstrate drug product comparability; (ii) Defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company's BLA submission schedule for LentiGlobin for SCD, particularly with respect to manufacturing; (iii) as a result of all the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Ontrak, Inc. (NASDAQ:OTRK)
OTRK Lawsuit on behalf of: investors who purchased November 5, 2020 - February 26, 2021
Lead Plaintiff Deadline : May 3, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/ontrak-inc-loss-submission-form?prid=14490&wire=1
According to the filed complaint, during the class period, Ontrak, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Ontrak's largest customer evaluated the Company on a provider basis, valuing Ontrak's performance based on achieving the lowest cost per medical visit rather than clinical outcomes or medical cost savings; (2) as a result, Ontrak's largest customer did not find the Company's program to be effective and was reasonably likely to terminate its contract with Ontrak; (3) because this customer accounted for a significant portion of the Company's revenue, the loss of the customer would have an outsized impact on Ontrak's financial results; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Athenex, Inc. (NASDAQ:ATNX)
ATNX Lawsuit on behalf of: investors who purchased August 7, 2019 - February 26, 2021
Lead Plaintiff Deadline : May 3, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/athenex-inc-loss-submission-form?prid=14490&wire=1
According to the filed complaint, during the class period, Athenex, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the data included in the Oral Paclitaxel plus Encequidar NDA presented a safety risk to patients in terms of an increase in neutropenia-related sequalae; (ii) the uncertainty over the results of the primary endpoint of objective response rate (ORR) at week 19 conducted by BICR; (iii) the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR; (iv) the Company's Phase 3 study that was used to file the NDA was inadequate and not well-conducted in a patient population with metastatic breast cancer representative of the U.S. population, such that the FDA would recommended a new such clinical trial; (v) as a result, it was foreseeable that the FDA would not approve the Company's NDA in its current form; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/639500/CLASS-ACTION-UPDATE-for-BLUE-OTRK-and-ATNX-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders
